Apogee Therapeutics Files 8-K

TL;DR

APGE filed an 8-K on 3/25 for Reg FD and exhibits.

AI Summary

On March 25, 2024, Apogee Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. Apogee Therapeutics, Inc. is a biotechnology company incorporated in Delaware, with its principal executive offices located in Waltham, MA.

Why It Matters

This 8-K filing indicates that Apogee Therapeutics, Inc. is providing updates related to disclosures and financial exhibits, which is standard for public companies to keep investors informed.

Risk Assessment

Risk Level: low — This filing is a routine 8-K for disclosures and exhibits, not indicating any immediate material adverse events.

Key Players & Entities

• Apogee Therapeutics, Inc. (company) — Registrant
• March 25, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• Waltham, MA (location) — Address of Principal Executive Offices

FAQ

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 per share APGE The Nasdaq Global Ma

Filing Documents

• tm249632d1_8k.htm (8-K) — 27KB
• tm249632d1_ex99-1.htm (EX-99.1) — 14KB
• 0001104659-24-038161.txt ( ) — 219KB
• apge-20240325.xsd (EX-101.SCH) — 3KB
• apge-20240325_lab.xml (EX-101.LAB) — 33KB
• apge-20240325_pre.xml (EX-101.PRE) — 22KB
• tm249632d1_8k_htm.xml (XML) — 4KB

01

Item 7.01 Regulation FD Disclosure. On March 25, 2024, Apogee Therapeutics, Inc. (the "Company") issued a press release announcing that it has initiated dosing in healthy volunteers in its first clinical trial for APG808, a novel subcutaneous extended half-life monoclonal antibody targeting IL-4R, which is being developed as a treatment for people living with moderate-to-severe chronic obstructive pulmonary disease, asthma and other inflammatory and immunology diseases. A copy of the press release is furnished herewith as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits . The following exhibit is being furnished herewith: EXHIBIT INDEX Exhibit No. Description 99.1 Press Release, dated March 25, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Apogee Therapeutics, Inc. Date: March 25, 2024 By: /s/ Michael Henderson, M.D. Name: Michael Henderson, M.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR